Zynex Inc (NASDAQ:ZYXI) Misses Q2 2025 Revenue and EPS Estimates, Shares Drop 11.66% After Hours

Zynex Inc (NASDAQ:ZYXI) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The medical technology company, which specializes in non-invasive pain management and rehabilitation devices, posted a revenue of $22.29 million, falling short of the consensus estimate of $27.92 million. Similarly, the company reported an EPS loss of $0.32, worse than the anticipated loss of $0.20.

Key Financial Highlights vs. Estimates

• Revenue Miss: Reported $22.29M vs. estimated $27.92M, a shortfall of approximately 20%.
• Wider EPS Loss: Posted -$0.32 per share compared to the projected -$0.20.
• After-Hours Reaction: Shares dropped sharply, declining nearly 11.66% in post-market trading.

Market Reaction & Recent Performance

The immediate market response reflects investor disappointment, as the stock extended its recent downward trend. Over the past month, Zynex shares have declined by 17.1%, with a more pronounced sell-off following the earnings release. The broader underperformance suggests concerns over the company’s ability to meet growth expectations.

Analyst Outlook & Future Estimates

Looking ahead, analysts remain cautious. For Q3 2025, revenue is projected at $30.18 million, with an estimated EPS loss of $0.16. Full-year 2025 estimates anticipate sales of $118.85 million and an EPS loss of $0.80. The lack of an explicit outlook in the press release leaves investors reliant on these forecasts, which now appear more uncertain given the Q2 miss.

Press Release Summary

Zynex emphasized its continued focus on expanding its product portfolio, including its NexWave and NeuroMove devices, as well as its monitoring solutions like the CM-1500 and CM-1600. However, the financial results indicate operational or demand challenges that may require further scrutiny in upcoming earnings calls or investor updates.

For a deeper dive into Zynex’s earnings history and future estimates, review the full details here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.